Tarek Hammad, MD, PhD
Executive Director, Epidemiology
Merck Research Laboratories
Web Site: www.DrTarekHammad.com
Dr. Hammad joined Merck Research Laboratories in 2013 as an Executive Director in the Department of Epidemiology. Prior to joining Merck, he was the Deputy Division Director of the US Food and Drug Administration’s Division of Epidemiology located in the Office of Surveillance and Epidemiology (OSE) in the Center for Drug Evaluation and Research (CDER). During his tenure in the FDA, Dr. Hammad represented the FDA in several multidisciplinary working groups, including, among many others, the Mini-Sentinel program and the CIOMS X Expert Working group tasked to develop a guidance document for meta-analysis of studies. In 2000, he joined the Divisions of Neurology and Psychiatry Drug Products in CDER as a drug safety Medical Reviewer and served as an active member of a multidisciplinary team which had the overall responsibility for pre- and post-marketing safety evaluation of neurology and psychiatry drugs in the Divisions. Subsequently, in 2004, Dr. Hammad joined OSE as a Senior Medical Epidemiologist to work on large electronic medical records and insurance claims databases assessing post-marketing safety issues. He served as the Analytic Epidemiology Team Leader (2004) and as the Associate Director of Epidemiology (2008) in the same Division. Dr. Hammad has authored over 60 peer-reviewed publications and made many presentations in various scientific conferences and other settings. He also holds several academic appointments, spanning various medical disciplines. More information about his background and experience can be found on his professional website: www.DrTarekHammad.com.
Tarek A. Hammad, George A. Neyarapally, Solomon Iyasu, Judy A. Staffa, Gerald Dal Pan. “The Future of Population-Based Postmarket Drug Risk Assessment: A Regulator’s Perspective”. Clinical Pharmacology & Therapeutics, advance online publication 10 July 2013. doi:10.1038/clpt.2013.118.
Tarek A Hammad, Azadeh Shoaibi, Mark Levenson, David Graham, Judy A Staffa, Aloka Chakravarty, Solomon Iyasu. Drug risk assessment and data reuse. A letter in response to Toh, et al. (2013), Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidem. Drug Safe. doi: 10.1002/pds.3478.
Tarek A. Hammad, Andrea V. Margulis, Yulan Ding, Marian M. Strazzeri, Holly Epperly. “Determining the predictive value of Read codes to identify congenital cardiac malformations in the UK Clinical Practice Research Datalink”. Pharmacoepidemiology and Drug Safety, 2013; 22: 1233–1238. DOI: 10.1002/pds.3511.
Marc B. Stone, Tarek A. Hammad. Fluoxetine and suicidal ideation in minor depression. Journal of Psychiatric Research. DOI information: 10.1016/j.jpsychires.2013.09.012.
Andrea V Margulis, Elizabeth M Kang, Tarek A Hammad “Patterns of use of antidepressants and antipsychotics across and within pregnancies in a population-based UK cohort”. Maternal and Child Health Journal 2013. DOI 10.1007/s10995-013-1419-2
Esther H. Zhou, Sigal Kaplan, Andrew Mosholder, David Moeny, Yulan Ding, Solomon Iyasu, Tarek A. Hammad. “Antidepressant Medication Dispensing among Montelukast Initiators”. Journal of Asthma, DOI: 10.3109/02770903.2013.823445.
Simone P. Pinheiro, Elizabeth M. Kang, Clara Y. Kim, Laura A. Governale, Esther H. Zhou, Tarek A. Hammad. “Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States”. Pharmacoepidemiology and drug safety 2013; 22: 1251–1257. DOI: 10.1002/pds.3481.
Andrea V. Margulis, Adel Abou-Ali, Marian M. Strazzeri, Yulan Ding, Fatmatta Kuyateh, Eric Y. Frimpong, Mark S. Levenson, Tarek A. Hammad. “Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD”. Pharmacoepidemiology and drug safety (2013). DOI: 10.1002/pds.3462.
Tarek A. Hammad, George A. Neyarapally, Simone P. Pinheiro, Solomon Iyasu, C. George Rochester, Gerald Dal Pan. “Reporting of Meta-Analyses of Randomized Controlled Trials with a Focus on Drug Safety: An Empirical Assessment”. Clinical Trials 2013; 10: 389–397.
Johnson KE, Beaton SJ, Andrade SE, Cheetham TC, Scott PE, Hammad TA, Dashevsky I, Cooper WO, Davis RL, Pawloski PA, Raebel MA, Smith DH, Toh S, Li DK, Haffenreffer K, Dublin S. “Methods of linking mothers and infants using health plan data for studies of pregnancy outcomes.” Pharmacoepidemiol Drug Saf. 2013 Apr 18. doi: 10.1002/pds.3443.
R Boggon, TP van Staa, M Chapman, AM Gallagher, TA Hammad, MA Richards “Cancer recording and mortality in the General Practice Research Database and linked cancer registries”. Pharmacoepidemiology and Drug Safety, 2013 Feb;22(2):168-75. doi: 10.1002/pds.3374.
Jarow Jonathan, Fang Xin, Tarek A Hammad. “Variability of Semen Parameters Over Time in Placebo-Treated Men”. Journal of Urology, 2013 May;189(5):1825-9. doi: 10.1016/j.juro.2012.11.077.
George A Neyarapally, Tarek A Hammad, Simone P Pinheiro, Solomon Iyasu. “Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies”. BMJ Open 2012;2:e001362.doi:10.1136/bmjopen-2012-001362
Tarek A. Hammad, Simone P. Pinheiro, George A. Neyarapally. “Secondary Use of Randomized Controlled Trials to Evaluate Drug Safety: a Review of Methodological Considerations”. Clinical Trials 2011; 8(5):559-570.
Ann W. McMahon1, Robert G. Pratt, Tarek A. Hammad, Steven Kozlowski, Esther Zhou, Susan Lu, Corrinne G. Kulick, Tarun Mallick and Gerald Dal Pan. “Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008”. Pharmacoepidemiology and Drug Safety 2010; 19: 921–933.
